Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 3 · 60%GRADE not reported 0 · 0%Very low 1 · 20%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Serious adverse events · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.3 [0.11, 0.8]
3 studies · 311 participants
Very low

Serious adverse events · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · people with surgically‐induced remission in Crohn's disease

5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Serious adverse events · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found